An AllTrials project

NCT05696392: An ongoing trial by Incyte Corporation

This trial is ongoing. It must report results 1 month, 1 week from now.

Full data

Full entry on ClinicalTrials.gov NCT05696392
Title An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS)
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date March 16, 2023
Completion date Jan. 22, 2025
Required reporting date Jan. 22, 2026, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov Dec. 12, 2025
Days late None